Tag Archive for: Cell Therapy

Blue Cell Therapeutics appoints leading cell therapy executive Miguel Forte MD, PhD, to its Board of Directors

/in

Miguel Forte, current President of the International Society for Cell & Gene Therapy (ISCT), joins Blue Cell as a Non-Executive Director Highly experienced executive with deep scientific expertise, who has helped lead numerous private and public cell therapy biotechs, establishing corporate structures and raising funds Appointment comes as Blue Cell advances its groundbreaking “off-the-shelf” allogeneic […]

Read more

Blue Cell Therapeutics appoints highly experienced pharma and biotech executive Olav Hellebø as Chairman of the Board of Directors

/in

Seasoned executive with three decades of experience in pharma and biotech Biotech board experience from Cytovation ASA, Antev Ltd, and Calliditas Therapeutics, and governance / senior leadership experience from UCB, Novartis and Schering-Plough (now Merck) Appointment comes as Blue Cell looks to progress its lead candidate, allogeneic stem cell treatment BlueC-231, into Phase 1/2a clinical […]

Read more

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025

/in

– Proprietary manufacturing process enables robust and scalable GMP-compliant manufacture of autologous engineered RMT products, including lead asset RTX001 in end-stage liver disease (ESLD). – Novel mode of action-based candidate testing suite enabled the discovery of RTX001, which shows enhanced anti-inflammatory and anti-fibrotic effects in vitro and in vivo. – The EMERALD Phase1/2 interventional study […]

Read more

Resolution Therapeutics to Host Virtual Webinar on Liver Disease with World Leading Hepatologist Arun Sanyal, M.D.

/in

Highlighting Clinical Data and Discovery Platform Following Presentations at EASL Congress 2024 Edinburgh and London, UK, 13 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease, today announces that it will host a virtual R&D webinar on Friday 28th June 2024 at 12.30 BST / 7.30 […]

Read more

Resolution Therapeutics Announces New Breakthrough Clinical Data for Macrophage Cell Therapy in End Stage Liver Disease at EASL 2024

/in

MATCH Phase 2 data underscores significant potential of macrophage cell therapy treatment for advanced liver cirrhosis Resolution Therapeutics presents novel discovery platform for engineered macrophage cell therapy to enhance therapeutic efficacy Edinburgh and London, UK, 5 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver […]

Read more